PHIBRO ANIMAL HEALTH CORP (PAHC) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001069899 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 26, 2026 | $396.7M | $21.7M | $0.52 | Filing |
| Mar 31, 2026 | May 6, 2026 | $383.5M | $24.0M | $0.59 | Filing |
| Dec 31, 2025 | Feb 4, 2026 | $373.9M | $27.5M | $0.67 | Filing |
| Sep 30, 2025 | Nov 5, 2025 | $363.9M | $26.5M | $0.65 | Filing |
| Jun 30, 2025 | Aug 27, 2025 | $378.7M | $17.2M | $0.43 | Filing |
| Mar 31, 2025 | May 7, 2025 | $347.8M | $20.9M | $0.51 | Filing |
| Dec 31, 2024 | Feb 5, 2025 | $309.3M | $3.2M | $0.08 | Filing |
| Sep 30, 2024 | Nov 6, 2024 | $260.4M | $7.0M | $0.17 | Filing |
What would PHIBRO ANIMAL HEALTH CORP have to report for its valuation to change?
At $37.98, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 6.0% a year, to $3.25. On that path the next quarter needs diluted EPS near $0.69, against $0.65 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 6.0% | 6.0% |
| EPS needed in final year | $3.25 | $3.25 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. PAHC goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.